Merck (MRK) Reports Positive Top-Line Results from Pivotal Phase 3 Trials Evaluating Combination of Doravirine/Islatravir for the Treatment of People with HIV-1 Infection
Go back to Merck (MRK) Reports Positive Top-Line Results from Pivotal Phase 3 Trials Evaluating Combination of Doravirine/Islatravir for the Treatment of People with HIV-1 Infection| Merck & Co. (NYSE: MRK) | Delayed: 113.87 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $113.87 | 52 Week High | $65.46 | |||
| Open | $113.87 | 52 Week Low | $47.97 | |||
| Day High | $113.87 | P/E | 77.46 | |||
| Day Low | $113.87 | EPS | $1.47 | |||
| Volume | 72,937 | |||||
